Association of Serum PCSK9 Levels with Antibiotic Resistance and Severity of Disease in Patients with Bacterial Infections Admitted to Intensive Care Units
暂无分享,去创建一个
M. Banach | Ž. Reiner | Y. Panahi | Parisa Kianpour | Tannaz Jamialahmadi | A. Sahebkar | A. vahedian-azimi | S. Ganjali | Mohamamd Amin Safarpour | Mahdi Chahabi | Saeed Solgi | T. Jamialahmadi
[1] Wei-Qi Wei,et al. A Genetic Approach to the Association Between PCSK9 and Sepsis , 2019, JAMA network open.
[2] C. Fjell,et al. Reduced Proprotein convertase subtilisin/kexin 9 (PCSK9) function increases lipoteichoic acid clearance and improves outcomes in Gram positive septic shock patients , 2019, Scientific Reports.
[3] Z. Ortutay,et al. Reduced plasma PCSK9 response in patients with bacteraemia is associated with mortality , 2019, Journal of internal medicine.
[4] Henry E. Wang,et al. PCSK9 loss-of-function variants and risk of infection and sepsis in the Reasons for Geographic and Racial Differences in Stroke (REGARDS) cohort , 2019, PloS one.
[5] G. Francis,et al. Impact of PCSK9 loss-of-function genotype on 1-year mortality and recurrent infection in sepsis survivors , 2018, EBioMedicine.
[6] A. Prat,et al. Low-density lipoprotein (LDL)-dependent uptake of Gram-positive lipoteichoic acid and Gram-negative lipopolysaccharide occurs through LDL receptor , 2018, Scientific Reports.
[7] A. Sahebkar,et al. PCSK9 and infection: A potentially useful or dangerous association? , 2018, Journal of cellular physiology.
[8] Ž. Reiner. PCSK9 inhibitors in clinical practice: Expectations and reality. , 2018, Atherosclerosis.
[9] F. Fallarino,et al. PCSK9 at the crossroad of cholesterol metabolism and immune function during infections , 2017, Journal of cellular physiology.
[10] D. Francisci,et al. Hepatitis C virus and proprotein convertase subtilisin/kexin type 9: a detrimental interaction to increase viral infectivity and disrupt lipid metabolism , 2017, Journal of cellular and molecular medicine.
[11] I. Pećin,et al. Prevention of cardiovascular disease in patients with familial hypercholesterolaemia: The role of PCSK9 inhibitors , 2017, European journal of preventive cardiology.
[12] J. Gromada,et al. Inhibition of PCSK9 does not improve lipopolysaccharide-induced mortality in mice[S] , 2017, Journal of Lipid Research.
[13] M. Banach,et al. PCSK9 and diabetes: is there a link? , 2017, Drug discovery today.
[14] John D. Davis,et al. Effects of RG7652, a Monoclonal Antibody Against PCSK9, on LDL-C, LDL-C Subfractions, and Inflammatory Biomarkers in Patients at High Risk of or With Established Coronary Heart Disease (from the Phase 2 EQUATOR Study). , 2017, The American journal of cardiology.
[15] M. Banach,et al. PCSK9 inhibitors in sepsis: a new potential indication? , 2017, Expert opinion on investigational drugs.
[16] A. Prat,et al. Differential Expression of PCSK9 Modulates Infection, Inflammation, and Coagulation in a Murine Model of Sepsis , 2016, Shock.
[17] S. Ishibashi,et al. Possible involvement of PCSK9 overproduction in hyperlipoproteinemia associated with hepatocellular carcinoma: A case report. , 2016, Journal of clinical lipidology.
[18] P. Ganz,et al. HIV and Hepatitis C–Coinfected Patients Have Lower Low‐Density Lipoprotein Cholesterol Despite Higher Proprotein Convertase Subtilisin Kexin 9 (PCSK9): An Apparent “PCSK9–Lipid Paradox” , 2016, Journal of the American Heart Association.
[19] C. Fjell,et al. Increased Plasma PCSK9 Levels Are Associated with Reduced Endotoxin Clearance and the Development of Acute Organ Failures during Sepsis , 2016, Journal of Innate Immunity.
[20] G. Francis,et al. The Central Role of Proprotein Convertase Subtilisin/Kexin Type 9 in Septic Pathogen Lipid Transport and Clearance. , 2015, American journal of respiratory and critical care medicine.
[21] Ž. Reiner. Management of patients with familial hypercholesterolaemia , 2015, Nature Reviews Cardiology.
[22] J. Mehta,et al. Cross-talk between LOX-1 and PCSK9 in vascular tissues. , 2015, Cardiovascular research.
[23] Ž. Reiner. PCSK9 inhibitors – past, present and future , 2015, Expert opinion on drug metabolism & toxicology.
[24] J. Mehta,et al. Hemodynamic shear stress via ROS modulates PCSK9 expression in human vascular endothelial and smooth muscle cells and along the mouse aorta. , 2015, Antioxidants & redox signaling.
[25] M. Reilly,et al. PCSK9 is a critical regulator of the innate immune response and septic shock outcome , 2014, Science Translational Medicine.
[26] A. Siddiqui,et al. Hepatitis C Virus Stimulates Low-Density Lipoprotein Receptor Expression To Facilitate Viral Propagation , 2013, Journal of Virology.
[27] G. Watts,et al. New Therapies Targeting apoB Metabolism for High-Risk Patients with Inherited Dyslipidaemias: What Can the Clinician Expect? , 2013, Cardiovascular Drugs and Therapy.
[28] K. Asehnoune,et al. Plasma PCSK9 is a late biomarker of severity in patients with severe trauma injury. , 2013, The Journal of clinical endocrinology and metabolism.
[29] M. Chrétien. My road to Damascus: how I converted to the prohormone theory and the proprotein convertases. , 2012, Biochemistry and cell biology = Biochimie et biologie cellulaire.
[30] K. Azzam,et al. Crosstalk between reverse cholesterol transport and innate immunity , 2012, Trends in Endocrinology & Metabolism.
[31] P. Ganz,et al. HIV and Hepatitis C – Coinfected Patients Have Lower Low-Density Lipoprotein Cholesterol Despite Higher Proprotein Convertase Subtilisin Kexin 9 ( PCSK 9 ) : An Apparent “ PCSK 9 – Lipid Paradox ” , 2016 .